Epidiolex, a prescription medicine made from a formulation of plant-derived cannabidiol (CBD), has been reclassified by the DEA from Schedule 1 to Schedule V – the lowest restriction classification available under federal law.
A Schedule V substance under the Controlled Substances Act are medicines deemed to possess a “low potential for abuse” and are non-addictive. A Schedule I substance is viewed by the DEA as having no medical use and a high potential for abuse. Among Schedule I drugs are heroin, LSD, meth, and cannabis.
Epidiolex, approved by the FDA in June 2018, has been shown effective in significantly reducing seizures caused by two rare forms of epilepsy that begin in childhood: Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS).
Commenting on the scheduling change, NORML’s Deputy Director Paul Armentano said:
“We anticipated that Epidiolex will be the first of many potential FDA-approved medicines based on the cannabis plant,” continued Armentano. “These are welcome alternatives. But these products should not be regulated in such a manner that patients no longer have ready access to herbal cannabis – a product that humans have used safely and effectively as a medicine for thousands of years and is approved today by statute in 31 states.”
Read more from the source: TheWeedBlog.com